KFF Report Finds TrumpRx Drug Prices Mixed Compared to Global Peers
A new Kaiser Family Foundation analysis shows that the TrumpRx platform delivers mixed results for prescription drug prices. While 17 brand-name drugs cost less than the average in peer countries, 15 are more expensive, and 13 are the most costly among all compared nations. The administration claims $700 million in savings, but experts advise patients to compare prices with insurance and other discount programs.
Key points
- KFF analyzed 32 brand-name drugs on TrumpRx against prices in 11 peer countries, finding 17 cheaper, 15 more expensive, and 13 the most expensive.
- The U.S. Department of Health and Human States claims the program has generated $700 million in savings for Americans.
- TrumpRx prices are based on 'Most Favored Nation' agreements with manufacturers, but do not guarantee the lowest global prices.
- Experts recommend that insured patients compare TrumpRx prices with their insurance co-pays, as insurance may be cheaper.
- Other discount platforms like GoodRx and Cost Plus Drugs offer alternative pricing options for consumers.
Background
The Trump administration launched TrumpRx in early 2026 as part of a broader 'Most Favored Nation' strategy to lower drug prices by tying them to rates in other developed nations. In September 2026, all 50 states joined the MFN pricing plan for Medicaid, projecting billions in savings. The platform expanded in May 2026 to include generic drugs, and in August, the administration reported the largest annual decline in prescription drug prices in over 60 years.
Why it matters
The mixed results from the KFF analysis highlight the limitations of the TrumpRx platform in delivering consistently lower drug prices compared to global peers. This underscores the need for patients to actively compare prices across different platforms and insurance options to ensure they are getting the best deal. The findings also raise questions about the effectiveness of the 'Most Favored Nation' policy in achieving its goal of aligning U.S. drug prices with those in other developed nations.
What to watch
The Trump administration is expected to continue expanding the TrumpRx platform and negotiating more 'Most Favored Nation' deals with pharmaceutical companies. Patients are advised to monitor their prescription costs and compare prices across different platforms and insurance plans. The KFF analysis may prompt further scrutiny of the effectiveness of the MFN policy in reducing drug prices for Americans.
Want the full story? Read the original reporting
Read on Yahoo Finance